NEWS5 MINUTE READ

Healey & AMG Center for ALS Announces New Investigational Drug Monepantel from PharmAust Limited will begin design for inclusion in HEALEY ALS Platform Trial

The HEALEY ALS Platform Trial is led by the Healey & AMG Center in collaboration with the Northeast ALS Consortium (NEALS). The trial is the first of its kind, allowing for multiple investigational drugs to be tested and evaluated simultaneously to accelerate the development of potential new ALS therapies. Drug candidates that enter the platform trial are chosen by a group of expert ALS scientists and members of the Healey & AMG Center Science Advisory Committee.

“We are thrilled to work with PharmAust leadership to design their regimen to investigate Monepantel for people with ALS” said Merit Cudkowicz, M.D., M.S.c., principal investigator and sponsor of the HEALEY ALS Platform Trial, director of the Sean M. Healey & AMG Center for ALS, chair of the Department of Neurology at MGH, and the Julieanne Dorn Professor of Neurology at Harvard Medical School. “We thank the Therapy Evaluation Committee for their review of potential therapies to add to the HEALEY ALS Platform Trial.”

The HEALEY ALS Platform Trial is a multicenter, double-blind, placebo-controlled, perpetual, adaptive platform trial testing multiple investigational products in parallel. The seventh regimen completed enrollment in May 2024.

Looks like we are the next cab off the rank NZT
Ready